Lixiang Education Received Notice of Failure to Satisfy Continued Listing Rule
May 09, 2024 05:20 ET
|
Lixiang Education Holding Co., Ltd.
LISHUI, China, May 09, 2024 (GLOBE NEWSWIRE) -- Lixiang Education Holding Co., Ltd. (the “Company” or NASDAQ: LXEH), a prestigious private education service provider in China, today announced that...
Global Ethylene Industry Report 2024-2030 Featuring SINOPEC, E. I. du Pont De Nemours and Co, Exxon Mobil, LyondellBasell Industries, Royal Dutch Shell, and SABIC
May 09, 2024 05:17 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Ethylene - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Ethylene Market to Reach 406.5 Million...
Los datos del ensayo de fase 2 sobre ERLEADA®▼(apalutamide) más terapia de privación androgénica tras prostatectomía radical en pacientes con cáncer de próstata localizado de alto riesgo muestran una tasa de recidiva libre de efectos bioquímicos del 100 por ciento más de dos años después de la cirugía
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
El estudio destaca la oportunidad de intensificar el tratamiento en esta población, ya que aproximadamente el 50 por ciento de los pacientes con cáncer de próstata localizado de alto riesgo (CPAR)...
Phase-II-Daten für ERLEADA®▼(apalutamide) plus Androgendeprivationstherapie nach radikaler Prostatektomie bei Patienten mit lokal begrenztem Hochrisiko-Prostatakrebs zeigen 100 prozentige biochemische Rezidivfreiheit mehr als zwei Jahre nach der Operation
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Die Studie unterstreicht die Möglichkeit einer Intensivierung der Behandlung in dieser Patientengruppe, da bei etwa 50 Prozent der Patienten mit lokalisiertem Hochrisiko-Prostatakrebs (High-risk...
Dati della Fase 2 di ERLEADA®▼(apalutamide) più trattamento di deprivazione androgenica in seguito a prostatectomia radicale in pazienti affetti da tumore della prostata localizzato ad alto rischio mostrano un tasso del 100 percento di assenza di recidiva biochimica più di due anni dopo l'intervento
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Lo studio evidenzia l'opportunità di intensificare il trattamento in tale popolazione poiché approssimativamente il 50 percento di pazienti con tumore della prostata localizzato ad alto rischio...
Données de phase 2 pour ERLEADA®▼(apalutamide) en association avec un traitement par privation androgénique après une prostatectomie radicale chez des patients atteints d’un cancer de la prostate localisé à haut risque : un taux de survie sans récidive biochimique de 100 pour cent plus de deux ans après l’intervention chirurgicale
May 09, 2024 05:11 ET
|
Janssen Cilag International NV
L’étude met en évidence la possibilité d’intensifier le traitement pour cette population, puisque près de 50 pour cent des patients atteints d’un cancer de la prostate localisé à haut risque (CPLHR)...
Nano Positioning System Market To Reach USD 254.8 Billion By 2032 | DataHorizzon Research
May 09, 2024 05:10 ET
|
DataHorizzon Research
Fort Collins, Colorado, May 09, 2024 (GLOBE NEWSWIRE) -- High demand for precision in the manufacturing industry drives industry developments. The nano positioning system market is experiencing...
Allot to Release First Quarter 2024 Earnings and Host Conference Call on May 29, 2024
May 09, 2024 05:06 ET
|
Allot
Hod Hasharon, Israel, May 09, 2024 (GLOBE NEWSWIRE) -- Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative network intelligence and security-as-a-service (SECaaS)...
Global Perlite Industry Research 2024: Market to Reach $1.9 Billion by 2030 - China and Greece Dominate Production
May 09, 2024 05:03 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Perlite - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Perlite Market to Reach $1.9 Billion by...
Hagar hf.: Skýrsla tilnefningarnefndar til aðalfundar 2024
May 09, 2024 05:00 ET
|
Hagar hf.
Aðalfundur Haga hf., kt. 670203-2120, verður haldinn fimmtudaginn 30. maí 2024 og hefst hann kl. 15:00 á Hilton Reykjavík Nordica (Vox Club), Suðurlandsbraut 2 í Reykjavík. Þann 19. mars 2024 var...